Omeros to present results from first pivotal Phase 3 trial of OMS302 at AAO annual meeting
Omeros Corporation today reported that it will present data from its first pivotal Phase 3 clinical trial evaluating OMS302 at the American Academy of Ophthalmology (AAO) Annual Meeting, which will take place from November 10 through November 13 in Chicago, Illinois.